Metabolic hypertension: concept and practice

Abstract

Hypertension is a serious public health problem worldwide. More than 60% of the risk factors for hypertension are associated with metabolic disturbances. Metabolic abnormalities increase the risk for hypertension and cause high blood pressure. Improving metabolic disturbances is beneficial for hypertension treatment. Due to the importance of metabolic abnormalities in the pathogenesis of hypertension, we propose a concept of metabolic hypertension. In this review, we discuss and review the clinical types, pathogenesis, risk evaluation and management of metabolic hypertension. Elucidation of the mechanism of metabolic hypertension should facilitate the design of novel pharmacotherapeutics and dedicated antihypertensive manipulations.

Keywords

hypertension / cardiometabolic risk factors / metabolic abnormalities

References

[1] Lee SR, Cha MJ, Kang DY, Oh KC, Shin DH, Lee HY. Increased prevalence of metabolic syndrome among hypertensive population Ten years’ trend of the Korean National Health and Nutrition Examination Survey. Int J Cardiol2011<month>Dec</month><day>20</day>. [Epub ahead of print] doi: 10.1016/j.ijcard.2011.11.095

[2] Pool PE. The case for metabolic hypertension: is it time to restructure the hypertension paradigm? Prog Cardiovasc Dis1993; 36(1): 1–38

[3] Zhu ZM. Metabolic hypertension. In: Zhu ZM. Metabolic syndrome: pathogenesis and clinical practice. Beijing: People’s Military Medical Press, 2005: 275–294 (in Chinese)

[4] Zhu ZM. Metabolic hypertension: an issue worth exploring. Chin J Hypertens (Zhonghua Gao Xue Ya Za Zhi)2006; 14(11): 859–860 (in Chinese)

[5] Zhu ZM. Metabolic syndrome: an obesity-related metabolic cardiovascular syndrome. Chin J Endocrino Metab (Zhonghua Nei Fen Mi Dai Xie Za Zhi)2007; 23(4): 291–293 (in Chinese)

[6] Xu XS, Yang WT, Liu DY, Zhong J, Tian ZQ, Yan ZC, Ni YX, Chen J, Zhao ZG, Zhu ZM. Cardiovascular and Renal Damage in Hypertensive Complicated with Metabolic Disorders. Chin J Hypertens (Zhonghua Gao Xue Ya Za Zhi)2006; 14(11): 894–898 (in Chinese)

[7] Chu S, Zhu D, Xiong M. Linkage analysis of candidate genes for glucose and lipid metabolism with essential hypertension. Nation Med J China (Zhonghua Yi Xue Za Zhi)2001; 81(1): 20–22 (in Chinese)

[8] Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation1999; 100(10): 1134–1146

[9] Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodés-Cabau J, Bertrand OF, Poirier P. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol2008; 28(6): 1039–1049

[10] Dang AM, Liu GZ. Uric acid and cardiovascular events. Chin J Cardiol (Zhonghua Xin Xue Guan Bing Za Zhi) 2003; 31(6): 478 (in Chinese)

[11] Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112(5): 666–673

[12] Bonny A, Lacombe F, Yitemben M, Discazeaux B, Donetti J, Fahri P, Megbemado R, Estampes B. The 2007 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens2008; 26(4): 825, author reply 825–826

[13] Gaciong Z, Symonides B. Hypertension 2010: what was new for the cardiologist? Expert Opin Pharmacother2010; 11(16): 2579–2597

[14] Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension2001; 37(4): 1053–1059

[15] Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther2008; 88(11): 1322–1335

[16] Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation1983; 67(5): 968–977

[17] Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol2008; 102(10 Suppl): 1K–34K

[18] He HB, Zhao ZG, Pu YF, Chen J, Ni YX, Zhong J, Liu HY, Li YS, Yan ZC, Liu DY, Zhu ZM. Types of abdominal obesity and risks of metabolic syndrome. Nation Med J China (Zhonghua Yi Xue Za Zhi)2008; 88(18): 1251–1254 (in Chinese)

[19] Pu YF, He HB, Zhao ZG, Chen J, Ni YX, Zhong J, Liu HY, Yan ZC, Zhu ZM. Quantitative assessment of visceral fat in patients with abdominal obesity and its clinical significance. Nation Med J China (Zhonghua Yi Xue Za Zhi)2008; 88(34): 2391–2394 (in Chinese)

[20] Malik S, Wong ND. Metabolic syndrome, cardiovascular risk and screening for subclinical atherosclerosis. Expert Rev Cardiovasc Ther2009; 7(3): 273–280

[21] Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol2006; 47(6): 1093–1100

[22] Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet2001; 358(9294): 1682–1686

[23] Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, Damasceno A, Ounpuu S, Yusuf S. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation2005; 112(23): 3554–3561

[24] Garnett SP, Baur LA, Srinivasan S, Lee JW, Cowell CT. Body mass index and waist circumference in midchildhood and adverse cardiovascular disease risk clustering in adolescence. Am J Clin Nutr2007; 86(3): 549–555

[25] Zhu ZM. Obesity and cardiovascular disease- from epidemiology to pathogenesis. Chin J Diabete (Zhongguo Tang Niao Bing Za Zhi)2006; 14(6): 402–404 (in Chinese)

[26] Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res2003; 11(11): 1278–1289

[27] Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev2006; 22(6): 423–436

[28] Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol2009; 53(5 Suppl): S35–S42

[29] Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care2008; 31(Suppl 2): S155–160

[30] Buyken AE, von Eckardstein A, Schulte H, Cullen P, Assmann G. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil2007; 14(2): 230–236

[31] Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res2009; 82(1): 9–20

[32] Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am2008; 37(3): 603–621, viii

[33] Groop L. Genetics of the metabolic syndrome. Br J Nutr2000; 83 (Suppl 1): S39–S48

[34] Norris JM, Rich SS. Genetics of glucose homeostasis: implications for insulin resistance and metabolic syndrome. Arterioscler Thromb Vasc Biol2012; 32(9): 2091–2096

[35] Monda KL, North KE, Hunt SC, Rao DC, Province MA, Kraja AT. The genetics of obesity and the metabolic syndrome. Endocr Metab Immune Disord Drug Targets2010; 10(2): 86–108

[36] Chuang LM. Human genetics of the metabolic syndrome. Asia Pac J Clin Nutr2008; 17(Suppl 1): 43–46

[37] Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest2011; 121(6): 2126–2132

[38] Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut2009; 58(8): 1091–1103

[39] Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature2011; 472(7341): 57–63

[40] Zhu ZM. Intervention of the critical component in metabolic syndrome: issues and challenges. Chin J Geriat Heart Brain Vessel Dis (Zhonghua Lao Nian Xin Nao Xue Guan Bing Za Zhi)2009; 11(6): 401–403 (in Chinese)

[41] Dominguez-Rodriguez A. Managing hypertension in cardiology practice: from individual risk factors and the metabolic syndrome to global cardiometabolic risk. Int J Clin Pract2008; 62(9): 1303–1304

[42] Zhu ZM. Should actively explore the comprehensive assessment of cardiometabolic risk. Chin J Cardiol (Zhonghua Xin Xue Guan Bing Za Zhi) 2007; 35(5): 387–389 (in Chinese)

[43] Zhu ZM. Intensive glycemic control and cardiovascular events reduction: confusion and enlightenment. Chin J Diabete (Zhongguo Tang Niao Bing Za Zhi)2009; 17(2): 85–87 (in Chinese)

[44] Yang D, Luo Z, Ma S, Wong WT, Ma L, Zhong J, He H, Zhao Z, Cao T, Yan Z, Liu D, Arendshorst WJ, Huang Y, Tepel M, Zhu Z. Activation of TRPV1 by dietary capsaicin improves endothelium-dependent vasorelaxation and prevents hypertension. Cell Metab2010; 12(2): 130–141

[45] Ma S, Yu H, Zhao Z, Luo Z, Chen J, Ni Y, Jin R, Ma L, Wang P, Zhu Z, Li L, Zhong J, Liu D, Nilius B, Zhu Z. Activation of the cold-sensing TRPM8 channel triggers UCP1-dependent thermogenesis and prevents obesity. J Mol Cell Biol2012; 4(2): 88–96

[46] Zhang LL, Yan Liu D, Ma LQ, Luo ZD, Cao TB, Zhong J, Yan ZC, Wang LJ, Zhao ZG, Zhu SJ, Schrader M, Thilo F, Zhu ZM, Tepel M. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res2007; 100(7): 1063–1070

[59] Wang P, Yan Z, Zhong J, Chen J, Ni Y, Li L, Ma L, Zhao Z, Liu D, Zhu Z. Transient receptor potential vanilloid 1 activation enhances gut glucagon-like peptide-1 secretion and improves glucose homeostasis. Diabetes2012; 61(8): 2155–2165

[47] Zhu ZM. Concern about the particularity of the diagnosis and treatment of obesity-induced hypertension. Chin J Geriat Heart Brain Vessel Dis (Zhonghua Lao Nian Xin Nao Xue Guan Bing Za Zhi)2008; 10(2): 85 (in Chinese)

[48] Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol2009; 53(5 Suppl): S28–S34

[49] Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens2007; 25(4): 841–848

[50] Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care2009; 32(1): 187–192

[51] Bahadir O, Uzunlulu M, Oguz A, Bahadir MA. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res2007; 30(1): 49–53

[52] He H, Zhao Z, Chen J, Ni Y, Zhong J, Yan Z, Li Y, Liu D, Pletcher MJ, Zhu Z. Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. J Hypertens2012; 30(7): 1430–1439

[53] Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab2009; 94(2): 410–415

[54] Zhu ZM. Prevention and treatment strategies for diabetic macrovascular disease: from intensive glycemic control to coordination and balance. Chin J Endocrino Metab(Zhonghua Nei Fen Mi Dai Xie Za Zhi)2009; 25(4): 361–365 (in Chinese)

[55] Ashrafian H, le Roux CW, Darzi A, Athanasiou T. Effects of bariatric surgery on cardiovascular function. Circulation2008; 118(20): 2091–2102

[56] Demaria EJ, Winegar DA, Pate VW, Hutcher NE, Ponce J, Pories WJ. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the Bariatric Outcomes Longitudinal Database. Ann Surg2010; 252: 559–566; discussion 566–567

[57] Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med2010; 61(1): 393–411

[58] Reis CE, Alvarez-Leite JI, Bressan J, Alfenas RC. Role of bariatric-metabolic surgery in the treatment of obese type 2 diabetes with body mass index<35 kg/m²: a literature review. Diabetes Technol Ther2012; 14(4): 365–372

Acknowledgements

This research was supported by grants from the National Basic Research Program of China (2012CB517805 and 2012CB517806) (Z.M.Z. and D.Y.L.) and National Natural Science Foundation of China (81130006) (Z.M.Z.).

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg